In Article 120, the MDR establishes its transitional provisions, including the transition periods. However, the descriptions of these transitional provisions and transition periods are worded in a very complex manner. As a result, manufacturers are at risk of misunderstanding them and therefore not complying with regulatory requirements or incurring unnecessary costs.
A flow chart in chapter 2 of this article summarizes the regulatory requirements and provides clarity. It is also available as a free download.
This article considers the further postponement of the MDR transition periods adopted by the EU Parliament in February 2023.
The discussion regarding transition periods is usually limited to the question of how long a device can be placed on the market. As a result, the MDR has a number of transition periods.
Manufacturers need, for example, to differentiate between the following aspects with regard to transition periods:
This article provides an overview of these transition periods.
Placing on the market of legacy devices
see flow chart (fig. 1)
It is about the first making available
Making legacy devices available and putting them into service
The restrictions ("sell-off rule") have been removed by the amending regulation.
The same transition periods apply to these devices.
The PLM must have the technical documentation to meet the MDR requirements for post-market surveillance and vigilance.
Person Responsible for Regulatory Compliance
Not required for manufacturers of legacy devices. See the detailed transition periods paragraph in the PRRC article.
May 26, 2021
With restrictions regarding EUDAMED; no restriction on monitoring and reporting (e.g., PSUR).
May 26, 2021
With restrictions regarding the EUDAMED
May 26, 2021 (MDR-devices)
The amending regulation requires an MDR Article 10-compliant quality system for manufacturers of legacy devices.
see tab. below
May 26, 2021
Initiated inspections may continue, but new reporting requirements apply.
Article 10 of the MDR does not apply to devices that benefit from the transition period. Explicitly excluded from this are the abovementioned requirements for post-market surveillance and vigilance, among others.
The summary can be found in this fact sheet for download
We have also prepared a consolidated version of the articles on the transitional periods.
In August 2023, the EU also published a flow chart on its website.
How long manufacturers can still place their existing devices under the old directives (MDD/AIMDD) on the market, make them available or put them (or have them put) into service depends, among other things, on the class of the device and the validity of any certificates.
If you still have questions about switching to MDR, feel free to benefit from the Johner Institute's free micro-consulting service.
First 6 months after publication
The next 18 months after that
MDR devices and legacy devices
No (new) requirements
|All requirements except registration of devices (except custom-made devices) (Article 29 (4)) and certificates (Article 56 (5))
Specifics for economic operators based in Germany
According to this publication in the Federal Gazette, special transitional provisions apply to economic operators based in Germany. Accordingly, manufacturers and their authorized representatives must already be registered directly in EUDAMED since 26.05.2021 and not in the national database of the BfArM, the DMIDS. The same applies to importers of MDR-compliant medical devices.
The date from which the UDI must be applied depends on the class of the device:
May 26, 2025
May 26, 2023
May 26, 2023
III and implantable devices
May 26, 2021
For reusable devices where the UDI has to be placed on the device itself, the MDR grants two additional years.
However, these transition periods regarding UDI do not apply to legacy devices, i.e., devices "which are compliant with the Medical Device Directives (MDD and AIMDD) and placed on the market after the application date of the Regulations". There are two other documents to consider here:
In the FAQ, the EU writes:
In order to facilitate the transition to the new system, the new Regulations give manufacturers the possibility to place products on the market after the general application dates of the new Regulations (and until 26 May 2024 at the latest) by virtue of valid Directive certificates. These legacy devices are not subject to UDI obligations but they should be registered in the Eudamed database. Timelines for registration as described under question 6 also apply to these products. More information on the operational aspects of the registration of legacy devices is available at the MDCG 2019-5 guidance document.
FAQ of the EU
If manufacturers do not place devices on the market under the MDR, but only legacy devices according to art 120 (3), Article 15 of the MDR does not yet apply under MDCG 2021-25. This means that these manufacturers do not yet have to designate a Person Responsible for Regulatory Compliance (PRRC).
Until now, we and also many others had interpreted this differently. The reason was that the obligations for post-market surveillance and vigilance must be fulfilled by all manufacturers from May 26, 2021. The PRRC is responsible for an effective post-market surveillance and vigilance process. The MDCG 2021-25 guidance also considers this aspect but concludes that article 15 is not yet applicable to manufacturers of legacy devices.
All manufacturers must implement effective processes for post-market surveillance and vigilance in all cases, only monitoring by the PRRC is not yet mandatory for manufacturers of legacy devices.
Details can also be found in the article on the PRRC in the section "transition periods".
Article 120 is entitled “Transitional provisions”. It also mentions the transition periods. The second paragraph is particularly relevant:
Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC as of May 25, 2017, which were still valid on May 26, 2021, and which have not been subsequently withdrawn, shall remain valid after the end of the period indicated on the certificate until the date specified in paragraph 3a of this Article for the relevant risk class of devices. Certificates issued by notified bodies in accordance with these Directives as of May 25, 2017, still valid on May 26, 2021, and expired before ... [the date of entry into force of this Regulation] shall be considered valid until the dates specified in paragraph 3a of this Article only if one of the following conditions is met:
a) Before the expiry of the certificate, the manufacturer and a notified body have signed a written agreement in accordance with the second subparagraph of section 4.3 of Annex VII to this Regulation on the conformity assessment of the device covered by the expired certificate or of a device intended to replace that device;
b) a competent authority of a Member State has granted an exemption from the applicable conformity assessment procedure in accordance with Article 59 (1) of this Regulation or has requested the manufacturer to carry out the applicable conformity assessment procedure in accordance with Article 97 (1) of this Regulation
MDR Article 120 (2)
If the manufacturer has a certificate issued before May 26, 2017, under the guidelines, it remains valid until the specified date. This excludes certificates issued under Annex IV of the Directives ("batch certification"), which were valid until May 27, 2022, at the latest.
If, on the other hand, the notified bodies' certificate was issued on or after May 26, 2017, and was still valid on May 26, 2021, these will remain valid until the stated deadlines (see paragraph 3 (a)). However, if these certificates expired before the amendment regulation came into force, i.e., before March 20, 2023, the extended validity will only apply if:
(3) By way of derogation from Article 5 and provided that the conditions referred to in paragraph 3c are met, the devices referred to in paragraphs 3a and 3b may be placed on the market or put into service until the dates referred to in those paragraphs.
(3a) Devices for which a certificate valid by virtue of paragraph 2 of this Article has been issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC may be placed on the market or put into service until the following dates:
(a) December 31, 2027, for all class III devices and class IIb implantable devices, except sutures, staples, dental fillings, braces, dental crowns, screws, wedges, dental or bone plates, wires, pins, clamps, and connectors;
(b) December 31, 2028, for class IIb devices other than those referred to in subparagraph (a) of this paragraph, class IIa devices, and class I devices placed on the market in a sterile condition or with a measuring function.
(3b) Devices for which the conformity assessment procedure under Directive 93/42/EEC did not require the involvement of a notified body, for which the declaration of conformity was drawn up before May 26, 2021, and for which the conformity assessment procedure under this Regulation requires the involvement of a notified body, may be placed on the market or put into service until December 31, 2028.
MDR Article 120 (3)
The third paragraph of Article 120 (a) and (b) can be interpreted as follows:
Legacy devices with a valid directive certificate may be placed on the market up to the specified time limits, depending on the risk class.
However, these extended transition periods only apply under certain conditions. These are mentioned in Paragraph 3 (c).
(3c) Devices referred to in Paragraphs 3a and 3b of this Article may be placed on the market or put into service only until the dates referred to in those Paragraphs if the following conditions are met:
a) The devices continue to comply with Directive 90/385/EEC or Directive 93/42/EEC, as the case may be;
b) there are no significant changes in the design and intended use;
c) the devices do not pose an unacceptable risk to the health or safety of patients, users, or other persons or to other aspects of public health protection;
d) the manufacturer has established a quality management system in accordance with Article 10, Paragraph 9, no later than May 26, 2024; and
e) the manufacturer or the authorized representative has, no later than May 26, 2024, submitted a formal application to a notified body in accordance with the first Subparagraph of Section 4.3 of Annex VII for conformity assessment for a device referred to in Paragraph 3a or 3b or for a device intended to replace that device, and the notified body and the manufacturer have signed a written agreement in accordance with the second Subparagraph of Section 4.3 of Annex VII no later than September 26, 2024.
(3d) By way of derogation from Paragraph 3 of this Article, the requirements of this Regulation on post-market surveillance, market surveillance, vigilance, and registration of economic operators and devices shall apply to devices referred to in Paragraphs 3a and 3b instead of the corresponding requirements of Directives 90/385/EEC and 93/42/EEC.
The third Paragraph of Article 120 (c) describes the conditions that must be met for the application of the extended transition periods.
The device continues to comply with the requirements of the MDD or AIMDD. This sounds logical and should also be ensured by the monitoring of the notified bodies and authorities.
The manufacturer has not made any significant changes to the device or intended purpose. What exactly is meant by this is explained by the MDCG in the document MDCG 2020-03.
The question of how significant changes may be so that they do not have to be considered "significant" is a particular cause for discussion. Please refer to the article on "Design Changes".
That the devices do not pose an unacceptable risk to safety and health should be ensured by compliance with the directives. Nevertheless, this is a monitoring task of the notified bodies and surveillance authorities. This is also made clear by the MDCG in guidance document MDCG 2022-04. This contains recommendations on the surveillance activities of legacy devices during the transition periods. It states:
"In cases where the audit activities reveal a major non-conformity, which may present an
unacceptable risk to the health or safety of patients, users, or other persons, the notified body needs to inform the relevant competent authority."
The requirements for a complete quality system, according to Article 10, Paragraph 9, have been supplemented by the amendment Regulation. Thus, it is no longer sufficient to implement only the processes for post-market surveillance and vigilance, according to the MDR. The latter must already be implemented in an MDR-compliant manner since May 26, 2021 (see 3 (d)).
This condition should also not be underestimated and should not be neglected. Manufacturers must have submitted an application for MDR certification to a notified body by May 26, 2024. It is unclear whether the application must only have been submitted by then or whether it must also have been positively examined by the notified bodies. This leaves room for interpretation and differences of opinion. We currently assume that this date only concerns the application but not the inspection by the notified bodies. The possibility of applying for MDR certification not for the actual legacy product but for a "replacing device" is interesting. However, it is unclear what the requirements are for this. For example, must the replacing device be equivalent, or can it be based on a different technology? Unfortunately, this also leaves room for interpretation. The MDCG should provide clarity on this as soon as possible.
In addition to the application, a signed contract with a notified body for MDR certification must be available by September 26, 2024.
(3e) Without prejudice to Chapter IV and Paragraph 1 of this Article, the notified body that issued the certificate referred to in Paragraph 3a of this Article shall remain responsible for the appropriate monitoring of all applicable requirements for the devices it has certified unless the manufacturer has agreed with a notified body whose designation has been made in accordance with Article 42 that it will perform such monitoring.
No later than September 26, 2024, the notified body that signed the written agreement referred to in Paragraph 3c (e) of this Article shall be responsible for monitoring the devices covered by the written agreement. Where the written agreement concerns a device intended to replace a device for which a certificate has been issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC, the monitoring shall be carried out in relation to the replaced device.
The arrangements for the transfer of monitoring from the notified body which issued the certificate to the notified body whose designation has been made in accordance with Article 42 shall be clearly set out in an agreement between the manufacturer and the notified body whose designation has been made in accordance with Article 42 and, where practicable, the notified body which issued the certificate. The notified body whose designation has been made in accordance with Article 42 shall not be responsible for conformity assessment activities carried out by the notified body that issued the certificate.
MDR Article 120 (3)
Paragraph 3 (e) regulates the surveillance activities and responsibilities of the notified bodies. As a rule, the notified body that issued the directive certificate is responsible for further monitoring within the transition periods. However, manufacturers may change their notified bodies, which will then take over the surveillance activities. This may be necessary, for example, if the current notified body has not (yet) been designated under the MDR. By September 26, 2024, at the latest, a notified body designated under the MDR must then have monitoring responsibility.
(3f) By way of derogation from Article 5, custom-made implantable devices of class III may be placed on the market or put into service until May 26, 2026, without a certificate issued by a notified body in accordance with the conformity assessment procedure referred to in the second Subparagraph of Article 52 (8), provided that the manufacturer or the authorized representative has submitted a formal application for conformity assessment to a notified body in accordance with Section 4.3, first Subparagraph, of Annex VII no later than September 26, 2024, and that the notified body and the manufacturer have concluded a written agreement in accordance with Section 4.3, first Subparagraph, of Annex VII no later than September 26, 2024. May 2024 at the latest to a notified body, and the notified body and the manufacturer have signed a written agreement in accordance with the second Subparagraph of Section 4.3 of Annex VII.
MDR Article 120 (3)
This means there is no longer a time limit for sell-off (I.e., for further making available and putting into service of legacy devices). This provision is intended to ensure that safe and important medical devices that have already been placed on the market continue to be available to health care systems and the patients who rely on them.
The term making available should be distinguished from placing on the market.
The fourth paragraph is comparatively easy to understand:
(4) Devices lawfully placed on the market pursuant to Directives 90/385/EEC and 93/42/EEC prior to 26 May 2021, and devices lawfully placed on the market from 26 May 2021 pursuant to paragraphs 3, 3a, 3b and 3f of this Article, may continue to be made available on the market or put into service.
MDR Article 120 (4)
This means that there is no sell-off period anymore. This provision is intended to ensure that "safe and important medical devices that have already been placed on the market continue to be available to healthcare systems and the patients who rely on them."
A distinction must be made between the terms "making available" and "placing on the market."
The eighth Paragraph only causes many readers to shake their heads. Who is supposed to understand this on first reading?
"(8) By way of derogation from Articles 10a, 10b (1) (a) and 11 (5) of Directive 90/385/EEC and from Articles 14 (1) and (2), 14a (1) (a) and (b) and 16 (5) of Directive 93/42/EEC, manufacturers, authorized representatives, importers and notified bodies which, during the period , starting on the later of the data referred to in point (d) of Article 123 (3) and ending 18 months later, comply with Article 29 (4), Article 31 (1) and Article 56 (5) of this Regulation, shall be deemed to comply with the rules and provisions adopted by the Member States pursuant to decision 2010/227/EU, in accordance with Article 10a of Directive 90/385/EEC or in accordance with Article 14 (1) and (2) of Directive 93/42/EEC, in accordance with Article 10b (1) (a) of Directive 90/385/EEC and in accordance with Article 14a (1 )(a) and (b) of Directive 93/42/EEC, and in accordance with Article 11 (5) of Directive 90/385/EEC and in accordance with Article 16 (5) of Directive 93/42/EEC, respectively."
MDR Article 120 (8)
In the context of EUDAMED, the MDR imposes the following requirements on legacy devices:
Article 120 (8) thus states that manufacturers of legacy devices, for example, who register themselves and their devices in EUDAMED, comply with the corresponding obligations under the old directives.
However, this obligation refers to the "period beginning on the later of the dates referred to in Article 123 (3) (d) and ending 18 months later".
In this letter d, the following data can be identified:
This means that in the context of EUDAMED and registration, manufacturers "only" have to fulfill the above-mentioned obligations during a period of 18 months. After that, all requirements regarding EUDAMED apply.
For those who wish to understand Paragraph 8 in more detail, here are the references cited:
Article 123 lists other deadlines that affect economic operators, e.g.:
The UDI carrier must be affixed on May 26, 2021, for implantable devices and class III devices, May 26, 2023, for class IIa and IIb devices, and May 26, 2025, for class I devices. This exemption does not apply to the issuance of the UDI.
The following documents are regulatory relevant and should be observed:
The pressure was great, and the complaints about the negative effects of the MDR could not be ignored by the EU Commission. It, therefore, postponed the transition periods several times. However, it has only partially remedied the problems as a result. Many harms have already occurred:
Nevertheless, the extension of the transition periods was an important step. However, the specifications, which have been revised several times, are now difficult to keep track of and still leave questions unanswered.